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Perspective: In a much larger randomized trial that included
nearly 2,900 patients with out-of-hospital cardiac arrest 
(N Engl J Med 2008;359:21-30), combination therapy with
epinephrine plus vasopressin did not improve outcomes
compared to epinephrine alone. This suggests that the
improved survival in the present study group was more a
result of therapy with corticosteroids than vasopressin.
Corticosteroids may exert the following beneficial effects
during and after CPR: improvement in contractile function
during and after ischemia, increase in peripheral arterial
tone, decrease in systemic inflammatory response, and atten-
uation of post-CPR adrenal insufficiency.  
Summary written by: Fred Morady, MD, FACC
Large Scale Replication and Meta-Analysis of
Variants on Chromosome 4q25 Associated With
Atrial Fibrillation
Kääb S, Darbar D, van Noord C, et al.
Eur Heart J 2009;Jan 13:[Epub ahead of print].
Study Design: Is the association between genetic variation on
chromosome 4q25 and atrial fibrillation (AF) reproducible
when applied to other cohorts?
Methods: This association was analyzed in four independent
cohorts, including 12,173 patients. The Framingham Heart
Study and Rotterdam Study are community-based longitudi-
nal studies. The Vanderbilt AF Registry and German AF
Network (AFNet) are case-control studies.
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Arrhythmias
Vasopressin, Epinephrine, and Corticosteroids for
In-Hospital Cardiac Arrest
Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al.
Arch Intern Med 2009;169:15-24.
Study Design: Does the combination of epinephrine, vaso-
pressin, and methylprednisolone improve survival compared
to epinephrine alone in patients with in-hospital cardiac
arrest (IHCA)?
Methods: One hundred patients with IHCA were randomly
assigned to receive 1 mg of epinephrine (control group, n =
52) during five cycles of cardiopulmonary resuscitation (CPR)
or the combination of 1 mg of epinephrine and 20 IU of vaso-
pressin during the first five CPR cycles and 40 mg of methyl -
prednisolone during the first cycle, followed by 300 mg/day of
hydrocortisone for up to 7 days (study group, n = 48).
Results: Return of spontaneous circulation was significantly
higher in the study group (81%) than in the control group
(52%). Survival to hospital discharge also was significantly
higher in the study group (19%) than in the control group
(4%).
Conclusions: Compared to epinephrine alone, the combination
of vasopressin, epinephrine, and corticosteroids improves
survival after IHCA.
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Results: Average risk-adjusted mortality rate was stable and
declining over the 2 years: 3.68% in 2003 and 3.61% in 2004.
In 2004, the average risk-adjusted mortality rate ranged from
1.39% in tier 1 hospitals to 6.40% in tier 4 hospitals. 
The sex-specific mortality rate was consistently higher for
women in all tiers, with the differential smallest (0.68%) in
tier 1 hospitals and greatest (2.67%) in tier 4 hospitals.
Conclusions: The sex differential increases from top- to 
bottom-tier hospitals, suggesting female beneficiaries could
benefit from having CABG performed at tier 1 hospitals.
Perspective: This study suggests that Medicare beneficiaries
should pay close attention to hospital performance rankings
for CABG based on lives saved. Improving the quality of care
in poorer-performing hospitals may improve CABG out-
comes. The difference in average risk-adjusted mortality rates
across hospital tiers is substantially larger than the overall
reduction in CABG mortality that has been achieved over the
last decade with clinical advances in performing the proce-
dure. Future research is needed to focus on the processes and
structures that differentiate the top performing hospitals from
the bottom performers, and how this knowledge can be trans-
lated to other hospitals.  
Summary written by: Debabrata Mukherjee, MD, FACC
Congenital Heart Disease
Association Between Intraoperative and Early
Postoperative Glucose Levels and Adverse
Outcomes After Complex Congenital Heart Surgery
Polito A, Thiagarajan RR, Laussen PC, et al.
Circulation 2008;118:2235-2242.
Study Question: What associations exist between perioperative
glucose exposure and morbidity after complex congenital
heart surgery?
Methods: Patients at a single center undergoing cardiac surgery
with a Risk Adjustment in Congenital Heart Surgery
(RACHS-1) category ≥3 over a 1-year period were included
(n = 378). Metrics of glucose control, including average, peak,
minimum, and SD of glucose levels were studied. Multiple
regression analyses were used to determine associations
between glucose control and both length of hospital stay and a
composite outcome of morbidity and mortality.
Results: For intraoperative glucose levels, only a minimum
glucose of ≤75 mg/dl was associated with increased risk of
reaching the composite endpoint (odds ratio, 3.1; 95% con-
fidence interval, 1.49-6.48). Only duration of hyperglycemia
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Results: Participants with AF (n = 3,508) were more likely to
be male and were older than referent participants. Single
nucleotide polymorphism (SNP) rs2200733 was associated
with AF in all four cohorts, with odds ratios (ORs) ranging
from 1.37 in Rotterdam (95% confidence interval [CI], 1.18-
1.59; p = 3.1 x 10-5) to 2.52 in AFNet (95% CI, 2.22-2.8; p
= 1.8 x 10-49). There also was a significant association
between AF and rs10033464 in Framingham (OR, 1.34; 95%
CI, 1.03-1.75; p = 0.031) and AFNet (OR, 1.30; 95% CI,
1.13-1.51; p = 0.0002), but not Vanderbilt (OR, 1.16; 95%
CI, 0.86-1.56; p = 0.33).
Conclusions: The noncoding SNPs rs2200733 and
rs10033464 are strongly associated with AF in four cohorts
of European descent.
Perspective: While hypertension and valvular heart disease are
important risk factors for AF, other independent genetic
factors have been shown to be associated with AF. A recent
genome-wide association study identified a haplotype block
on chromosome 4q25 associated with AF. The SNPs that
define this haplotype block are located in a noncoding
region of the genome. The current study provides strong
additional support for the association of AF with genetic
variation at this region. The underlying mechanism for this
genetic association remains elusive, although the closest
gene (transcription factor PITX2) is an attractive candidate.  
Summary written by: Daniel T. Eitzman, MD, FACC 
Cardiovascular Surgery
Sex Differences in Hospital Risk-Adjusted
Mortality Rates for Medicare Beneficiaries
Undergoing CABG Surgery
Culler SD, Simon AW, Brown PP, Kugelmass AD, Reynolds MR, Rask KJ.
Arch Intern Med 2008;168:2317-2322.
Study Question: What are the overall and sex-specific differ-
ences after coronary artery bypass graft surgery (CABG) on
Medicare beneficiaries in the risk-adjusted mortality rates
across four performance tiers?
Methods: A retrospective analysis was done using a Medicare
Provider Analysis and Review file of all Medicare beneficiaries
who underwent CABG during 2003 and 2004. Logistic
regression models controlling for demographics, comorbidi-
ties, and cardiac risk factors were used to predict the
probability of in-hospital mortality. Hospitals performing at
least 52 CABG surgeries during a fiscal year (at least 17
female patients) were ranked into four tiers, based on the
number of lives saved.
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significantly more common in the carriers (12.1% vs. 8.0%;
hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.07-
2.19; p = 0.01). Carriers were also more likely to develop
stent thrombosis (2.6% vs. 0.8%; HR, 3.09; 95% CI, 1.19-
8.00; p = 0.02).
Conclusions: Among persons treated with clopidogrel, carriers
of a reduced-function CYP2C19 allele had lower platelet
inhibition in response to clopidogrel and were more likely to
suffer adverse ischemic events.
Perspective: This landmark paper is likely to change clinical
management of patients with ACS. While prasugrel was
superior to clopidogrel in the TRITON–TIMI 38 trials, the
difference is probably mediated by poor bioavailability of
clopidogrel in some patients. The risk of morbid events in
patients who were not carriers of the reduced function allele
was low and similar to the risk in the overall prasugrel-
treated arm. It would be helpful to assess the outcome of a
similar cohort randomized to prasugrel to see if the benefit
is restricted to carriers of the reduced function allele. I envi-
sion a future where genetic screen for the polymorphism is
part of the routine clinical care, with clopidogrel being used
in 70% of the noncarriers of the allele and prasugrel being
used in the remainder.  
Summary written by: Hitinder S. Gurm, MBBS, FACC 
Glucose Control and Vascular Complications in
Veterans With Type 2 Diabetes
Duckworth W, Abraira C, Moritz T, et al., on behalf of the VADT
Investigators.
N Engl J Med 2009;360:129-139.
Study Question: What are the effects of intensive glucose con-
trol on cardiovascular events in patients with long-standing
type 2 diabetes mellitus?
Methods: The investigators randomly assigned 1,791 military
veterans who had a suboptimal response to therapy for type 2
diabetes to receive either intensive or standard glucose control.
Mean number of years since the diagnosis of diabetes was
11.5, and 40% of the patients had already had a cardiovascular
event. The goal in the intensive-therapy group was an absolute
reduction of 1.5 percentage points in the glycated hemoglobin
level compared with the standard-therapy group. The primary
outcome was time from randomization to the first occurrence
of a major cardiovascular event.
Results: Median follow-up was 5.6 years. Median glycated
hemoglobin levels were 8.4% in the standard-therapy group
and 6.9% in the intensive-therapy group. The primary out-
come occurred in 264 standard-therapy and 235 intensive-
(glucose >126 mg/dl) was associated with longer duration of
hospitalization (p < 0.001). For the first 72 hours after sur-
gery, average glucose <110 mg/dl, or >143 mg/dl, minimum
glucose ≤75 mg/dl, and peak glucose ≥250 mg/dl were all
associated with greater odds of reaching the composite 
morbidity-mortality endpoint.
Conclusions: The optimal postoperative glucose range may be
from 110-126 mg/dl. Further prospective study is warranted.
Perspective: The primary limitation of this study is its retro-
spective design, which precludes any assumptions of causality.
While patients with lower blood glucose had poorer out-
comes, this may have been reflective of their inability to
generate an appropriate stress response. Conversely, elevated
postoperative blood glucose may have been reflective of
patients who were more ill in the postoperative period.
Although this study provides information regarding outcomes
of children with various glucose values postoperatively, it can-
not be used to demonstrate efficacy of tight glycemic control
or the optimal range for blood glucose postoperatively.  
Summary written by: Timothy B. Cotts, MD, FACC  
General Cardiology
Cytochrome P-450 Polymorphisms and Response
to Clopidogrel 
Mega JL, Close SL, Wiviott SD, et al. 
N Engl J Med 2008;360:354-362.
Study Question: What is the clinical impact of polymorphism
of cytochrome P-450 among patients treated with clopido-
grel?
Methods: The association between functional genetic variants
in cytochrome P-450 genes, plasma concentrations of active
drug metabolite, and platelet inhibition in response to clopi-
dogrel was tested in 162 healthy subjects. The association
between these variants and clinical outcomes was evaluated in
1,477 patients with acute coronary syndromes (ACS) who
were treated with clopidogrel in the TRITON–TIMI 38 trial.
Results: Thirty-four percent of the healthy volunteers were
carriers of at least one CYP2C19 reduced-function allele,
and this cohort had lower levels of active metabolite and a
25% relative (9% absolute) reduction in maximal platelet
aggregation in response to clopidogrel compared with non-
carriers (p < 0.001). Among the TRITON-TIMI subgroup,
27% of the patients were carriers of the low function allele.
The primary composite endpoint (risk of death from cardio-
vascular causes, myocardial infarction, or stroke) was
Eagle, Cannon
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therapy patients (hazard ratio [HR] in the intensive-therapy
group, 0.88; 95% confidence interval [CI], 0.74-1.05; 
p = 0.14). There was no significant difference between the
groups in any component of the primary outcome or rate of
death from any cause (HR, 1.07; 95% CI, 0.81-1.42; p =
0.62). No differences between the two groups were observed
for microvascular complications. The rates of adverse events,
predominantly hypoglycemia, were 17.6% in the standard- 
therapy and 24.1% in the intensive-therapy group.
Conclusions: Intensive glucose control in patients with poorly
controlled type 2 diabetes had no significant effect on the
rates of major cardiovascular events, death, or microvascular
complications.
Perspective: This study, along with the ADVANCE and
ACCORD studies, examined intensive glucose control in
different populations with different approaches and came to
similar conclusions that intensive glucose control did not
reduce cardiovascular events in patients with type 2 diabetes.
Data suggest that intensive glycemic control earlier in the
disease course may potentially produce benefit, especially if
severe hypoglycemia is avoided. Optimal management of
hypertension, dyslipidemia, and other cardiovascular risk
factors appears to be the most effective approach to prevent-
ing cardiovascular morbidity and mortality in patients with
type 2 diabetes.  
Summary written by: Debabrata Mukherjee, MD, FACC 
Cytochrome P450 2C19 Polymorphism in Young
Patients Treated With Clopidogrel After
Myocardial Infarction: A Cohort Study
Collet JP, Hulot JS, Pena A, et al.
Lancet 2009;373:309-317.
Study Question: What is the clinical impact of the
CYP2C19*2 polymorphism of cytochrome P450 2C19
(CYP2C19)?
Methods: The authors investigated the outcome of 259 young
patients (ages <45 years) who survived a first myocardial
infarction (MI) and were treated with clopidogrel for at least a
month. All patients underwent CYP2C19*2 determination.
The primary endpoint was a composite of death, MI, and
urgent coronary revascularization occurring during exposure to
clopidogrel. Follow-up was every 6 months. The secondary
endpoint was angiographically proven stent thrombosis.
Results: Most of the patients were noncarriers (n = 186),
whereas 64 were heterozygous (*1/*2), and 9 were homozy-
gous (*2/*2) (n = 9) for the CYP2C19*2 variant. There was no
difference in the baseline characteristics between the carriers
and noncarriers. The composite primary endpoint occurred
more frequently in carriers than in noncarriers (15 vs. 11 events;
hazard ratio [HR], 3.69; 95% confidence interval [CI], 1.69-
8.05; p = 0.0005). Carriers had higher event rates (per 100
person-years) for cardiovascular death (1.45 vs. 0.26, p = 0.1)
and MI (7.27 vs. 1.58, p = 0.001). Carriers were more likely to
develop stent thrombosis (6.79 vs. 1.14 events per 1,000
patient-years; HR, 6.02; 95% CI, 1.81-20.04; p = 0.0009).
Conclusions: The CYP2C19*2 genetic variant is a major deter-
minant of prognosis in young patients who are receiving
clopidogrel treatment after MI.
Perspective: This is the first key publication demonstrating the
clinical impact and genetic basis of clopidogrel resistance.
Recent studies have demonstrated that inadequate response to
clopidogrel is mainly secondary to low plasma levels of clopi-
dogrel metabolite (J Am Coll Cardiol 2008;52:1968-77).
Polymorphisms of CYP2C19 (Blood 2006;108:2244-7) are
associated with a marked decrease in platelet inhibition in
response to clopidogrel, and this is likely related to inadequate
generation of the active metabolite. Results of this study cor-
roborate the high incidence of MI and death in CYP2C19*2
carriers seen in other studies (J Am Coll Cardiol 2008;51:1925-
34), and suggest that we are likely on the threshold of
gene-guided antiplatelet therapy.  
Summary written by: Hitinder S. Gurm, MBBS, FACC
Cardiovascular Disease Risk Prediction With and
Without Knowledge of Genetic Variation at
Chromosome 9p21.3
Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM.
Ann Intern Med 2009;150:65-72.
Study Question: Does knowledge of 9p21.3 gene variation
improve cardiovascular risk prediction over traditional clinical
risk factors?
Methods: Subjects were 22,129 female white health professionals
without major chronic disease and participating in the
Women’s Genome Health Study, prospectively followed over a
median of 10.2 years for incident cardiovascular disease
(CVD). Polymorphism at rs10757274 on chromosome 9p21.3,
along with additional CVD risk factors, were analyzed.
Results: Polymorphism at rs10757274 was associated with an
adjusted hazard ratio for incident cardiovascular disease of
1.25 (95% confidence interval [CI], 1.04-1.51) for the AG
genotype and 1.32 (CI, 1.07-1.63) for the GG genotype.
However, the addition of the genotype to a prediction model
based on traditional risk factors, hs-CRP, and family history
of premature MI had no effect on model discrimination, and
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confirmed a reduction in mortality of 38% (RR, 0.62; 95%
CI, 0.39-1.00; p = 0.048).
Conclusions: The results of this meta-analysis suggest an
improvement of survival in the patients treated with the tar-
geted therapies approved for PAH.
Perspective: This meta-analysis includes several entirely differ-
ent drug classes and trials with the heterogeneity of PAH
(e.g., idiopathic, scleroderma, congenital, etc.). Despite that
limitation, it provides evidence of a major survival benefit at a
mean of 14.3 weeks, in part because of the 1.1% per month
mortality in the control group, most of whom are World
Health Organization (WHO) class IV with right heart failure.
Subgroup analysis according to the different classes of drugs
or with baseline exercise capacity, as assessed by 6MWD, did
not show statistically significant heterogeneity in the effects
on mortality. The authors suggest that the results have not
been driven by one class of drugs or by a group of patients
with a specific disease severity. That is not consistent with
clinical experience in which mortality is highly related to func-
tional class, right heart failure, and specific associated diseases.  
Summary written by: Melvyn Rubenfire, MD, FACC 
Early and Long-Term Outcomes of Heart Failure in
Elderly Persons, 2001-2005 
Curtis LH, Greiner MA, Hammill BG, et al.
Arch Intern Med 2008;168:2481-2488. 
Study Question: Are the improvements in heart failure (HF)
management reflected in trends in early and long-term mor-
tality and hospital readmission? 
Methods: This was a retrospective cohort study of 2,540,838
elderly Medicare beneficiaries hospitalized with HF between
2001 and 2005. Early and long-term all-cause mortality and
hospital readmission and patient- and hospital-level predic-
tors of these outcomes were examined.
Results: Unadjusted in-hospital mortality declined from 5.1%
to 4.2% during the study (p < 0.001), but 30-day, 180-day,
and 1-year all-cause mortality remained fairly constant at
11%, 26%, and 37%, respectively. Nearly one in four patients
were readmitted within 30 days of the index hospitalization,
and two-thirds were readmitted within 1 year. Controlling
for patient- and hospital-level covariates, the hazard of all-
cause mortality at 1 year was slightly lower in 2005 than in
2001 (hazard ratio, 0.98; 95% confidence interval, 0.97-0.99),
and the hazard of readmission did not decline significantly.
Conclusions: Early and long-term all-cause mortality and hos-
pital readmission rates remain high and have improved little
did not improve the Net Reclassification Improvement score
(-0.2%; p = 0.59) or the Integrated Discrimination
Improvement score (0.0; p = 0.18).
Conclusions: Genetic variation in chromosome 9p21.3 was
associated with incident cardiovascular disease, but did not
improve on the discrimination or classification of predicted
risk achieved with traditional risk factors, hs-CRP, and fam-
ily history of premature MI.
Perspective: Genetic variation at chromosome 9p21.3 is asso-
ciated with incident CVD; however, it has been unclear
whether screening for this polymorphism would improve risk
prediction. The current study demonstrates that there is no
clinical utility in determining 9p21.3 gene variant status in
white women at this time. Although knowledge of novel
gene variants may eventually lead to valuable insight into the
pathophysiology of complex diseases and new therapeutic
targets, the current clinical usefulness of this information
remains uncertain.  
Summary written by: Daniel T. Eitzman, MD, FACC
Heart Failure/Transplant
A Meta-Analysis of Randomized Controlled Trials
in Pulmonary Arterial Hypertension 
Galiè N, Manes A, Negro L, Palazzini M, Bacchi Reggiani ML, Branzi A.
Eur Heart J 2009;Jan 20:[Epub ahead of print]. 
Study Question: Does treatment with pulmonary arterial
hypertension (PAH)-specific drugs improve survival? 
Methods: The authors performed a meta-analysis of all ran-
domized, placebo-controlled trials with PAH-specific drugs
available in the Medline database from January 1990 to
October 2008, including only studies with a placebo com-
parator arm. The sensitivity analysis also included studies
comparing two active treatment arms. The main outcome
measure was all-cause mortality.
Results: Twenty-one trials were included in the primary analy-
sis (3,140 patients) and two additional studies (59 patients)
were included in the sensitivity analysis. The cumulative rela-
tive risk (RR) estimate of hospitalizations was a reduction of
61% (p < 0.001), and number needed to treat to prevent one
hospitalization was 19.9. Average increase in 6-minute walk
distance (6MWD) was 35.6 m or about 10.8% when com-
pared to baseline values. All-cause mortality in the control
group was 3.8%. Active treatments were associated with a
reduction in mortality of 43% (RR, 0.57; 95% confidence
interval [CI], 0.35-0.92; p = 0.023); the sensitivity analysis
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with time. The need to identify optimal management strate-
gies for these clinically complex patients is urgent.
Perspective: The study findings need to be interpreted in the
context that currently management of elderly HF patients is
not optimal. The importance of ‘core-measures’ medications
(e.g., angiotensin-converting enzyme inhibitors, beta-blockers,
and aldosterone blockade) for HF patients is one small step in
improving therapy in elderly HF patients. Bridging the gap
between evidence and practice should continue to be the key
goal of the practicing clinician to improve therapy in the eld-
erly with HF.  
Summary written by: Ragavendra R. Baliga, MBBS, FACC 
Interventional Cardiology
Gender Differences Among Patients With Acute
Coronary Syndromes Undergoing Percutaneous
Coronary Intervention in the American College of
Cardiology-National Cardiovascular Data Registry
(ACC-NCDR)
Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A.
Am Heart J 2009;157:141-148. 
Study Question: Do gender-related differences continue to
exist, as related to the management and outcomes of
patients with acute coronary syndromes (ACS)?
Methods: Patients admitted with ACS (unstable angina
[UA]/non–ST-elevation myocardial infarction [NSTEMI]
or STEMI) and who received a percutaneous coronary
intervention (PCI), and were included in the American
College of Cardiology-National Cardiovascular Data
Registry (ACC-NCDR) database from January 1, 2004 to
March 30, 2006, were included in this study.
Results: A total of 199,690 patients were included in the
cohort; 131,664 were men and 68,026 were women. Women
were more likely to present with UA or NSTEMI compared
to men (82% vs. 77%, p < 0.001). Women were more likely
to be older and have more comorbidities. Women were less
likely to have smoked or to have had prior PCI/coronary
artery bypass grafting. Women in both ACS categories had
less high-risk angiographic features compared to men, but
women with STEMI were more likely to have had cardio-
genic shock or nondialysis-dependent renal failure. Women
were less likely to receive aspirin or glycoprotein IIb/IIIa
inhibitors, and were less likely to receive aspirin or statins at
time of discharge. Similar rates of in-hospital mortality were
observed for women and men; however, women had higher
rates of cardiogenic shock, congestive heart failure, bleeding
events, or vascular complications. Rates of subacute stent
thrombosis were less among women compared to men (0.43%
vs. 0.57%, p = 0.0003).
Conclusions: Women, despite having fewer high-risk angio-
graphic complications, continue to have higher rates of
in-hospital complications. Examining methods for modify-
ing in-hospital management of female ACS patients may
reduce post-PCI complications.
Perspective: These findings suggest the need for further exami-
nation of ACS management in women. Reducing
periprocedural complications will assist in improving long-
term outcomes for women with heart disease.  
Summary written by: Elizabeth A. Jackson, MD, FACC  
The Use of Intravenous Enoxaparin in Elective
Percutaneous Coronary Intervention in Patients
With Renal Impairment: Results From the SafeTy
and Efficacy of Enoxaparin in PCI Patients, An Inter -
nationaL Randomized Evaluation (STEEPLE) Trial
White HD, Gallo R, Cohen M, et al.
Am Heart J 2009;157:125-131.
Study Question: What is the relative safety of enoxaparin for
percutaneous coronary intervention (PCI) compared with
unfractionated heparin (UFH) in patients with reduced renal
function?
Methods: In this subset analysis of the STEEPLE trial,
patients undergoing elective PCI received a bolus of intra-
venous enoxaparin (0.5 or 0.75 mg/kg, or activated clotting
time (ACT)-adjusted UFH, stratified by planned glycopro-
tein (GP) IIb/IIIa inhibitor use. The target ACT was
200-300 in patients treated with GP IIb/IIIa inhibitors and
300-350 seconds in patients treated without GP IIb/IIIa
inhibitors. Renal impairment (creatinine clearance ≤60
ml/min) was present in 659 (19%) of the patients.
Results: Bleeding complications were more frequent in patients
with renal dysfunction (major bleeding 2.7% vs. 1.5%, p =
0.04), whereas there was no difference in the incidence of
death, nonfatal myocardial infarction, or urgent target vessel
revascularization between patients with and without renal
impairment (5.7% vs. 6.5%). Enoxaparin was associated with
less major bleeding than UFH in patients with normal renal
function (0.9% for enoxaparin 0.5 mg/kg or 1.0% for enoxa-
parin 0.75 mg/kg vs. 2.6% with UFH), and less major
bleeding with impaired renal function (2.6% or 1.8% vs.
3.8%). There was no difference in minor bleeding or ischemic
events with enoxaparin- or UFH-treated patients.
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Conclusions: Single bolus enoxaparin was associated with sim-
ilar ischemic events and a trend for less major bleeding
compared with UFH in patients with renal impairment
undergoing PCI.
Perspective: Enoxaparin use in patients with severe renal dys-
function is associated with increased bleeding events. In this
subset analysis, severe renal dysfunction was present in only
1% of patients, and even the subset with moderate dysfunction
was underpowered to detect differences in outcome between
enoxaparin and UFH. It would be premature to assume safety
or efficacy of enoxaparin for PCI in patients with renal dys-
function based on these data.  
Summary written by: Hitinder S. Gurm, MBBS, FACC 
Noninvasive Cardiology
Myocardial Blood Flow in Patients With Low-Flow,
Low-Gradient Aortic Stenosis: Differences Between
True and Pseudo-Severe Aortic Stenosis. Results
From the Multicentre TOPAS (Truly or Pseudo-
Severe Aortic Stenosis) Study
Burwash IG, Lortie M, Pibarot P, et al.
Heart 2008;94:1627-1633.
Study Question: Do myocardial blood flow and myocardial flow
reserve differ in low-flow, low-gradient aortic stenosis (AS)
depending on whether there is underlying true-severe AS or
pseudo-severe AS?
Methods: In 36 patients with low-flow, low-gradient AS,
dynamic [13N] ammonia positron emission tomography
(PET) perfusion imaging was performed at rest (n = 36) and
during dipyridamole stress (n = 20) to quantify myocardial
blood flow and myocardial flow reserve. Dobutamine
echocardiography was used to classify patients as true-severe
AS (n = 18) or pseudo-severe (n = 18) based on the indexed
projected effective orifice area (EOAI) at a normal flow rate
of 250 ml/s (EOAIproj ≤ or >0.55 cm2/m2).
Results: Compared with healthy controls (n = 14), patients
with low-flow, low-gradient AS had higher resting mean
myocardial blood flow (0.83 ± 0.21 vs. 0.69 ± 0.09 ml/min/g,
p = 0.001), reduced hyperemic myocardial blood flow (1.16 ±
0.31 vs. 2.71 ± 0.50 ml/min/g, p < 0.001), and impaired
myocardial flow reserve (1.44 ± 0.44 vs. 4.00 ± 0.91, p <
0.001). Resting myocardial blood flow and myocardial flow
reserve correlated with indices of AS severity in low-flow,
low-gradient AS with the strongest relationship observed for
EOAIproj (rs = -0.50, p = 0.002 and rs = 0.61, p = 0.004,
respectively). Compared with pseudo-severe AS, true-severe
AS had a trend to a higher resting myocardial blood flow,
similar hyperemic blood flow, but a significantly smaller
myocardial flow reserve (1.19 ± 0.26 vs. 1.76 ± 0.41, p =
0.003). A myocardial flow reserve <1.8 had an accuracy of
85% for distinguishing true-severe from pseudo-severe AS.
Conclusions: Low-flow, low-gradient AS is characterized by
higher resting myocardial blood flow and reduced myocar-
dial flow reserve that relates to the AS severity. The degree
of myocardial flow reserve impairment differs between true-
severe and pseudo-severe AS, and may be of value for
distinguishing these entities.
Perspective: Patients with true-severe low-flow, low-gradient
AS benefit from surgical aortic valve replacement.
Dobutamine stress echocardiography traditionally is used to
distinguish true-severe AS from pseudo-severe AS. On
dobutamine infusion, left ventricular contractile augmenta-
tion with increased forward cardiac output results in higher
gradients and persistent low valve area in patients with true
AS, but an increase in valve area and no significant increase
in gradients in patients with pseudo-AS. However, among
some patients with severely decreased systolic function, or in
others with concomitant coronary artery disease and
inducible ischemia during dobutamine infusion, left ventric-
ular contractility may not substantially improve. Since the
therapeutic implications are substantial, using PET scanning
to accurately distinguish patients with an equivocal response
to dobutamine could have clinical implications in a subset of
patients with low-flow, low-gradient AS of unclear nature.  
Summary written by: David S. Bach, MD, FACC  
Prevention/Vascular
Modulation of Blood Pressure by Central
Melanocortinergic Pathways
Greenfield JR, Miller JW, Keogh JM, et al.
N Engl J Med 2009;360:44-52.
Study Question: What is the association between central
melanocortinergic signaling and blood pressure in overweight
or obese subjects?
Methods: The authors compared blood pressure, heart rate,
and urinary catecholamine levels in overweight or obese sub-
jects with a loss-of-function mutation in the melanocortin 4
receptor (MC4R) versus equally overweight subjects with
normal MC4R function. They also reported the response to
the use of an MC4R agonist in 28 volunteer overweight or
obese subjects.
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Results: Subjects with MC4R deficiency had markedly lower
prevalence of hypertension (24% vs. 53%, p = 0.009). After
exclusion of subjects taking antihypertensive medications,
blood pressure levels were significantly lower in the MC4R-
deficient subjects than in controls, with mean systolic blood
pressure of 123 ± 14 versus 131 ± 12 mm Hg (p < 0.05).
Diastolic blood pressure means were also significantly differ-
ent; 73 ± 10 versus 79 ± 7 mm (p < 0.05). The authors also
reported significant differences in increases in heart rate upon
awakening (p = 0.007) and heart rate upon euglycemic hyper-
insulinemia exposure (p < 0.001), with significantly lower
heart rate in the MC4R-deficient subjects. Twenty-four hour
urinary norepinephrine excretion was also significantly lower
in the MC4R-deficient subjects (p < 0.05). Exposure to 1.0
mg of MC4R agonist in overweight or obese controls resulted
in significant increases in systolic blood pressure (9.3 ± 1.9
mm Hg) and diastolic blood pressure (6.6 ± 1.1 mm Hg)
compared with placebo (p < 0.001) after 24 hours. Differences
in blood pressure were not explained by insulin levels.
Conclusions: These studies suggest melanocortinergic signal-
ing is involved in the control of human blood pressure
through an insulin-independent mechanism.
Perspective: An important area of research in hypertension
could be the role of melanocortinergic signaling in the
hypertensive response of the metabolic syndrome, or obesity-
related hypertension. This may suggest opportunities for
therapeutic intervention for hypertension and/or the hyper-
tension associated with overweight/obesity. The metabolic
syndrome is associated with increases in sympathetic activa-
tion, systemic inflammation, hypertension, and dyslipidemia.
These data suggest that melanocortin may play an important
role in the hypertension associated with obesity, and that
this association may be independent of insulin. It is early,
but this may be important to our understanding of the
hypertension associated with metabolic syndrome—a signifi-
cant and growing public health problem.  
Summary written by: James B. Froehlich, MD, FACC  
Relationship Between Blood Pressure and Outdoor
Temperature in a Large Sample of Elderly
Individuals: The Three-City Study
Alperovitch A, Lacombe JM, Hanon O, et al.
Arch Intern Med 2009;169:75-80.
Study Question: Is there a relationship between blood pressure
and outdoor temperature in the elderly?
Methods: The authors presented data from the large Three-City
Study (3C study), looking at the relationship between demen-
tia and vascular disease in 8,801 subjects ≥65 years not living
in an institution. Outdoor temperature was recorded at 11:00
a.m. each day. The authors investigated the relationship
between variations in blood pressure and temperature at the
time of baseline blood pressure measurement, as well as the
blood pressure measurement at 2-year follow-up.
Results: Both systolic and diastolic blood pressure values var-
ied across the seasons and across quintiles of outdoor
temperature at the time of blood pressure measurement.
Increasing temperature was associated with decreased sys-
tolic blood pressure, with an observed 8 mm Hg decrease
between the lowest and highest outdoor temperature quin-
tiles. Differences in blood pressure between baseline and
follow-up were strongly related to outdoor temperature,
such that higher temperature at follow-up was associated
with a greater decrease in blood pressure. 
Conclusions: Outdoor temperature and blood pressure corre-
lated strongly in the elderly, especially in those ≥age 80.
Periods of extreme temperatures should prompt careful
monitoring of blood pressure and antihypertensive treat-
ment in the elderly.
Perspective: This well-documented study suggests that either
cold weather is associated with increases in blood pressure
or warmer weather is associated with decreases in blood
pressure, or both. This observation could have important
implications for the assessment and treatment of hyperten-
sion in the elderly. The underlying mechanism of this
difference is uncertain. Possibilities include differences in
diet, hydration, sympathetic activity, or physical activity
between higher and lower temperature seasons.
Importantly, the investigators maintained a consistent
ambient room temperature throughout this study, suggest-
ing that outdoor weather conditions have an effect
independent of the ambient temperature at the time of
blood pressure measurement. Whatever the underlying
mechanism, clinicians should consider the seasons and out-
door temperature—especially when practicing in climates
that experience a large variation in seasonal temperature—
when assessing the need for antihypertensive treatment.  
Summary written by: James B. Froehlich, MD, FACC  
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